News | Contrast Media | August 15, 2017

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

New clinical and research guidelines urge caution when using gadolinium-based contrast, which evidence suggests can accumulate in the brain

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

August 15, 2017 — The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast agents during MRI scans. Emerging research suggests gadolinium-based contrast agents, injected in a patient's veins to brighten tissues in MRI images, accumulate in the brain. More than 300 million doses of such drugs have been administered since their introduction in 1987.

"Small amounts of gadolinium deposit in certain parts of the brain in people who undergo repeated gadolinium-based contrast agent enhanced exams," said Vikas Gulani, M.D., Ph.D., associate professor of radiology, urology and biomedical engineering at Case Western Reserve University School of Medicine, member of the Case Comprehensive Cancer Center, and director of magnetic resonance imaging at University Hospitals Cleveland Medical Center. "The ISMRM response is a review of the literature and a series of recommendations on what the community ought to do in response to this phenomenon." Gulani helped craft the new recommendations and served as first author for the review, featured on the cover of The Lancet Neurology.

In the review, Gulani and other experts suggest if gadolinium is not needed for a particular exam, it should not be administered. A risk-benefit analysis should happen for all exams. "Nearly everyone needs an MRI scan at some point, often contrast enhanced," Gulani said. "The idea that some gadolinium could be depositing in the brain is disconcerting to patients. In that situation, putting the risk and benefits into context is important." If gadolinium is needed, it should be administered and the choice of agent is dependent on a large number of factors, only one of which is the deposition phenomenon.

Defining harm is an important consideration. Gadolinium-based contrast agents have a proven track record for accurate diagnosis and treatment monitoring of a large number of diseases including cancer, neurological pathology, heart disease, liver disease, and many other important conditions afflicting adults and children. They are associated with few side effects, the most serious of which are extremely infrequent and affect already sick patients with severe kidney failure. The new review does not suggest sweeping changes in the use of MRI contrast agents, as at present, there is no evidence linking the brain deposits to health risks. However, it provides clarity about the previously unknown phenomenon of gadolinium deposition in the brain and provides guidance for future research.

For more information: www.thelancet.com/neurology

Related Content

Hitachi Healthcare Americas Introduces SynergyDrive MRI Workflow Solution
Technology | Magnetic Resonance Imaging (MRI) | November 21, 2017
November 21, 2017 — At the 2017 Radiological Society of North America (RSNA) annual meeting, Nov. 26-Dec.
Study Unveils Brain Changes During Extended Space Missions
News | Neuro Imaging | November 14, 2017
November 14, 2017 — More people today are poised to explore space than ever before; those who do will experience the
Synthetic CT Images Suitable for Prostate Cancer Radiotherapy Planning
News | Treatment Planning | November 14, 2017
Spectronic Medical announced that new data for their MRIPlanner software, generating synthetic computed tomography (sCT...
News | Magnetic Resonance Imaging (MRI) | November 13, 2017
Aspect Imaging announced last week that it received CE marking for the neonatal-dedicated Embrace Neonatal Magnetic...
Hitachi Healthcare Highlights Benefits of High-Field Open MRI in New Supplement

Click here to view the supplement.

News | Magnetic Resonance Imaging (MRI) | November 13, 2017
A new 24-page publication from Hitachi Healthcare details the benefits of High-Field Open MRI and is now available for...
Siemens Healthineers Introduces Share360 Tailored Service Portfolio
News | Imaging | November 10, 2017
November 10, 2017 — To address the specific needs of...
Johns Hopkins Researchers, Carestream Give Presentations on Medical Imaging Advances at RSNA
News | Digital Radiography (DR) | November 09, 2017
November 9, 2017 — Researchers from The Johns Hopkins University School of Medicine and Carestream Health scientists
3D CT image reconstruction of the thoracic organs and the heart using Philips software.
Sponsored Content | Webinar | Advanced Visualization | November 07, 2017
The CME webinar “Innovation and Success in 3D-inspired Development of the Business and Clinical Practice,” will take
Post-Concussion Brain Changes Persist for Pre-Teen Hockey Players
News | Magnetic Resonance Imaging (MRI) | November 02, 2017
Young hockey players who have suffered concussions may still show changes in the white matter of the brain months after...
Siemens Healthineers Announces First U.S. Installation of Magnetom Vida 3T MRI Scanner
News | Magnetic Resonance Imaging (MRI) | November 02, 2017
Mallinckrodt Institute of Radiology at Washington University School of Medicine, St. Louis, recently became the first U...
Overlay Init